FDA approves hearing implant for high- and low-frequency hearing loss

Synchrony EAS Hearing Implant System--Courtesy of MED-EL USA

The FDA has approved MED-EL’s hearing implant that combines a cochlear implant and an audio processor for people with both high- and low-frequency hearing loss.

People with high-frequency hearing loss tend to have difficulty understanding speech when there is background noise even with a hearing aid. Enter the Synchrony EAS (electric acoustic stimulation) Hearing Implant System, which stimulates the auditory nerve with a cochlear implant and amplifies sounds with an audio processor, according to a statement.

“The EAS System has the potential to close the gap for people who have high-frequency hearing loss, but whose residual low-frequency hearing would have made them ineligible for a cochlear implant up until now,” said MED-EL North America CEO Raymond Gamble in the statement.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

In a clinical trial, 92% of participants said they were better able to hear in background noise and 90% said they were satisfied with the device, MED-EL said in the statement. Patients with the EAS device did twice as well on speech understanding tests as they did with their hearing aids before they received the implant.

The EAS system is approved for patients 18 and older who have normal to moderate hearing loss in low frequencies and sloping or severe to profound hearing loss in high frequencies, according to the statement.


Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.